Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) insider Shamik Parikh sold 45,887 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the transaction, the insider directly owned 272,713 shares in the company, valued at $245,441.70. This trade represents a 14.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Humacyte Stock Up 11.1%
Humacyte stock traded up $0.09 during midday trading on Wednesday, hitting $0.92. 4,271,551 shares of the company were exchanged, compared to its average volume of 6,504,970. The company’s fifty day moving average price is $0.84 and its 200-day moving average price is $1.05. The company has a market cap of $203.64 million, a PE ratio of -1.61 and a beta of 2.31. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. Humacyte, Inc. has a fifty-two week low of $0.55 and a fifty-two week high of $2.93.
Humacyte (NASDAQ:HUMA – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%. On average, research analysts predict that Humacyte, Inc. will post -0.32 EPS for the current fiscal year.
Institutional Investors Weigh In On Humacyte
Humacyte News Roundup
Here are the key news stories impacting Humacyte this week:
- Positive Sentiment: Humacyte said its Symvess vascular graft is now under contract with the U.S. Department of Veterans Affairs Strategic Acquisition Center, which should make the product easier to access across 170 VA hospitals and may support broader adoption. Article Title
- Positive Sentiment: TD Cowen reportedly raised its price target on HUMA to $1.50 from $1.00, which can reinforce investor optimism around the stock’s potential. Article Title
- Neutral Sentiment: HC Wainwright updated its earnings estimates across several future periods, but the note still points to continued losses and only modest expected improvement over time.
- Negative Sentiment: The analyst revisions included lower EPS expectations for FY2026, FY2027 and FY2028, underscoring that Humacyte is still expected to remain unprofitable for the foreseeable future.
Analysts Set New Price Targets
Several research firms have issued reports on HUMA. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a report on Tuesday, April 28th. Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. BTIG Research dropped their price objective on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Finally, Benchmark dropped their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.57.
View Our Latest Stock Report on HUMA
Humacyte Company Profile
Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.
The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.
Featured Stories
- Five stocks we like better than Humacyte
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
